Eli Lilly and Company ranks in an above-average position in its peer group, with the profile driven primarily by growth. Price action is not yet fully confirming the underlying structural profile.
Peer-relative scores, weakest to strongest
Eli Lilly and Company develops pharmaceutical products, focusing on obesity and vaccine treatments.
LLY is priced based on growth in obesity treatments rather than its base business. With revenue growth at 56% year-on-year, the market focuses on the impact of obesity drugs, so every new trial or guidance update influences expectations for future growth. This growth focus means LLY is more driven by obesity therapies than traditional pharma, and the market values it as a high-growth stock rather than a defensive blue chip. Because the market prices LLY on continued obesity momentum, even small deviations from expectations are met with outsized price reactions—reflected in a 1-year volatility of 34.5%, well above the large-cap pharma median. A weak obesity quarter or a trial setback leads to a sharp rerating.
Break down LLY's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.